Skip to main content
. Author manuscript; available in PMC: 2018 Dec 4.
Published in final edited form as: Nat Struct Mol Biol. 2018 Jun 4;25(6):505–514. doi: 10.1038/s41594-018-0069-x

Figure 8: Predictions of the effects of small molecule compounds and cardiomyopathy-causing mutations on the contractility of β-cardiac myosin at the single molecule level.

Figure 8:

Both the overall cycle (kcat) and the strongly bound state (kdet) can be slowed or accelerated by activators, inhibitors, HCM, and DCM mutations. It is the aggregate effects on the parameters of power production which discriminates activating (activators, HCM mutations) from inhibitory perturbations (inhibitors, DCM mutations).